RU2003122189A - Сульфамидотиенопиримидины - Google Patents
Сульфамидотиенопиримидины Download PDFInfo
- Publication number
- RU2003122189A RU2003122189A RU2003122189/04A RU2003122189A RU2003122189A RU 2003122189 A RU2003122189 A RU 2003122189A RU 2003122189/04 A RU2003122189/04 A RU 2003122189/04A RU 2003122189 A RU2003122189 A RU 2003122189A RU 2003122189 A RU2003122189 A RU 2003122189A
- Authority
- RU
- Russia
- Prior art keywords
- formula
- solvates
- compounds
- physiologically acceptable
- acceptable salts
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims 22
- 150000003839 salts Chemical class 0.000 claims 15
- 239000012453 solvate Substances 0.000 claims 15
- 239000003814 drug Substances 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 229940079593 drug Drugs 0.000 claims 6
- 125000004432 carbon atom Chemical group C* 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 239000004615 ingredient Substances 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 230000006806 disease prevention Effects 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 claims 2
- 206010002383 Angina Pectoris Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 201000006306 Cor pulmonale Diseases 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 208000008469 Peptic Ulcer Diseases 0.000 claims 2
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 2
- 208000004186 Pulmonary Heart Disease Diseases 0.000 claims 2
- 208000001647 Renal Insufficiency Diseases 0.000 claims 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 201000009961 allergic asthma Diseases 0.000 claims 2
- 201000010105 allergic rhinitis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 210000000748 cardiovascular system Anatomy 0.000 claims 2
- 238000007889 carotid angioplasty Methods 0.000 claims 2
- 208000023819 chronic asthma Diseases 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000002993 cycloalkylene group Chemical group 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 230000000968 intestinal effect Effects 0.000 claims 2
- 230000007794 irritation Effects 0.000 claims 2
- 201000006370 kidney failure Diseases 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 201000005857 malignant hypertension Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 208000011906 peptic ulcer disease Diseases 0.000 claims 2
- 230000002093 peripheral effect Effects 0.000 claims 2
- 230000008855 peristalsis Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 208000028591 pheochromocytoma Diseases 0.000 claims 2
- 230000002980 postoperative effect Effects 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 150000003180 prostaglandins Chemical class 0.000 claims 2
- 208000002815 pulmonary hypertension Diseases 0.000 claims 2
- 208000017443 reproductive system disease Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 206010043554 thrombocytopenia Diseases 0.000 claims 2
- 208000019553 vascular disease Diseases 0.000 claims 2
- 239000005541 ACE inhibitor Substances 0.000 claims 1
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 201000000057 Coronary Stenosis Diseases 0.000 claims 1
- 229940118365 Endothelin receptor antagonist Drugs 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 229910002651 NO3 Inorganic materials 0.000 claims 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims 1
- 241000972349 Ocoa Species 0.000 claims 1
- 208000031481 Pathologic Constriction Diseases 0.000 claims 1
- 102000011016 Type 5 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 claims 1
- 108010037581 Type 5 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 claims 1
- 102000055135 Vasoactive Intestinal Peptide Human genes 0.000 claims 1
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 239000002160 alpha blocker Substances 0.000 claims 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 229960004676 antithrombotic agent Drugs 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 239000000480 calcium channel blocker Substances 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 238000007887 coronary angioplasty Methods 0.000 claims 1
- 210000004351 coronary vessel Anatomy 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 230000003291 dopaminomimetic effect Effects 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000002308 endothelin receptor antagonist Substances 0.000 claims 1
- -1 heteroaromatic radical Chemical class 0.000 claims 1
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 claims 1
- 239000004033 plastic Substances 0.000 claims 1
- 229920003023 plastic Polymers 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 208000037804 stenosis Diseases 0.000 claims 1
- 230000036262 stenosis Effects 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 0 **1C=CC(CNc2c(c(CCCC3)c3[s]3)c3nc(*)n2)=C*(*)C=C1 Chemical compound **1C=CC(CNc2c(c(CCCC3)c3[s]3)c3nc(*)n2)=C*(*)C=C1 0.000 description 1
- NZDUSONSEXDYTH-UHFFFAOYSA-N COc1ccc(CNc2nc(CS(N(CC3)CCC3C(O)=O)=O)nc3c2c(CCCC2)c2[s]3)cc1Cl Chemical compound COc1ccc(CNc2nc(CS(N(CC3)CCC3C(O)=O)=O)nc3c2c(CCCC2)c2[s]3)cc1Cl NZDUSONSEXDYTH-UHFFFAOYSA-N 0.000 description 1
- JTCKRFKSRKHQNC-UHFFFAOYSA-N COc1ccc(CNc2nc(CS(NCCN3CCOCC3)=O)nc3c2c(CCCC2)c2[s]3)cc1Cl Chemical compound COc1ccc(CNc2nc(CS(NCCN3CCOCC3)=O)nc3c2c(CCCC2)c2[s]3)cc1Cl JTCKRFKSRKHQNC-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10064994A DE10064994A1 (de) | 2000-12-23 | 2000-12-23 | Sulfamidothienopyrimidine |
| DE10064994.7 | 2000-12-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2003122189A true RU2003122189A (ru) | 2004-12-27 |
Family
ID=7668967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2003122189/04A RU2003122189A (ru) | 2000-12-23 | 2001-12-03 | Сульфамидотиенопиримидины |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7019013B2 (enExample) |
| EP (1) | EP1353927B1 (enExample) |
| JP (1) | JP4550361B2 (enExample) |
| KR (1) | KR20030062438A (enExample) |
| CN (1) | CN1483035A (enExample) |
| AR (1) | AR035524A1 (enExample) |
| AT (1) | ATE302781T1 (enExample) |
| BR (1) | BR0115996A (enExample) |
| CA (1) | CA2432582C (enExample) |
| CZ (1) | CZ20031815A3 (enExample) |
| DE (2) | DE10064994A1 (enExample) |
| ES (1) | ES2247007T3 (enExample) |
| HU (1) | HUP0302515A3 (enExample) |
| MX (1) | MXPA03005714A (enExample) |
| PL (1) | PL361733A1 (enExample) |
| RU (1) | RU2003122189A (enExample) |
| SK (1) | SK8432003A3 (enExample) |
| WO (1) | WO2002051848A2 (enExample) |
| ZA (1) | ZA200305659B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6849638B2 (en) * | 2001-04-30 | 2005-02-01 | Bayer Pharmaceuticals Corporation | 4-amino-5,6-substituted thiopheno [2,3-d] pyrimidines, pharmaceutical compositions containing the same, and their use in the treatment or prevention of pde7b-mediated diseases and conditions |
| MX2007012313A (es) | 2006-04-19 | 2007-11-21 | Boehringer Ingelheim Int | Dihidrotienopirimidinas para el tratamiento de enfermedades inflamatorias. |
| EP1847543A1 (de) | 2006-04-19 | 2007-10-24 | Boehringer Ingelheim Pharma GmbH & Co. KG | Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen |
| US8071596B2 (en) | 2007-01-12 | 2011-12-06 | Concert Pharmaceuticals, Inc. | Endothelin receptor antagonists |
| US8080549B2 (en) * | 2007-01-12 | 2011-12-20 | Concert Pharmaceuticals, Inc. | Endothelin receptor antagonists |
| EP2117538A1 (en) | 2007-01-24 | 2009-11-18 | Glaxo Group Limited | Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-) |
| CA2702518A1 (en) | 2007-10-19 | 2009-04-23 | Boehringer Ingelheim International Gmbh | New piperazino-dihydrothienopyrimidine derivatives |
| BRPI0817781A2 (pt) | 2007-10-19 | 2019-09-24 | Boehringer Ingelheim Int | piperazino-diidroteinopirimidinas substituídas com heterociclo |
| PT2215092E (pt) * | 2007-10-19 | 2012-04-10 | Boehringer Ingelheim Int | Piperidino-di-hidrotienopirimidinas substituídas |
| EP2595993B1 (en) | 2010-07-23 | 2018-04-18 | President and Fellows of Harvard College | Tricyclic proteasome activity enhancing compounds |
| US20130059866A1 (en) | 2011-08-24 | 2013-03-07 | Boehringer Ingelheim International Gmbh | Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma |
| US9802954B2 (en) | 2011-08-24 | 2017-10-31 | Boehringer Ingelheim International Gmbh | Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma |
| JP2015504919A (ja) | 2012-01-25 | 2015-02-16 | プロテオステイシス セラピューティクス，インコーポレイテッド | プロテアソーム活性を調節する化合物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19644228A1 (de) * | 1996-10-24 | 1998-04-30 | Merck Patent Gmbh | Thienopyrimidine |
| DE19752952A1 (de) * | 1997-11-28 | 1999-06-02 | Merck Patent Gmbh | Thienopyrimidine |
| DE19819023A1 (de) * | 1998-04-29 | 1999-11-04 | Merck Patent Gmbh | Thienopyrimidine |
| EP1323719A1 (en) * | 1999-03-30 | 2003-07-02 | Nippon Soda Co., Ltd. | Thienopyrimidine compounds and salts thereof and process for the preparation of the same |
-
2000
- 2000-12-23 DE DE10064994A patent/DE10064994A1/de not_active Withdrawn
-
2001
- 2001-12-03 CN CNA018212190A patent/CN1483035A/zh active Pending
- 2001-12-03 RU RU2003122189/04A patent/RU2003122189A/ru not_active Application Discontinuation
- 2001-12-03 AT AT01271992T patent/ATE302781T1/de not_active IP Right Cessation
- 2001-12-03 DE DE50107230T patent/DE50107230D1/de not_active Expired - Lifetime
- 2001-12-03 CZ CZ20031815A patent/CZ20031815A3/cs unknown
- 2001-12-03 CA CA2432582A patent/CA2432582C/en not_active Expired - Fee Related
- 2001-12-03 MX MXPA03005714A patent/MXPA03005714A/es not_active Application Discontinuation
- 2001-12-03 BR BR0115996-8A patent/BR0115996A/pt not_active Application Discontinuation
- 2001-12-03 KR KR10-2003-7008265A patent/KR20030062438A/ko not_active Withdrawn
- 2001-12-03 PL PL01361733A patent/PL361733A1/xx unknown
- 2001-12-03 HU HU0302515A patent/HUP0302515A3/hu unknown
- 2001-12-03 JP JP2002552942A patent/JP4550361B2/ja not_active Expired - Fee Related
- 2001-12-03 WO PCT/EP2001/014102 patent/WO2002051848A2/de not_active Ceased
- 2001-12-03 US US10/451,183 patent/US7019013B2/en not_active Expired - Fee Related
- 2001-12-03 ES ES01271992T patent/ES2247007T3/es not_active Expired - Lifetime
- 2001-12-03 SK SK843-2003A patent/SK8432003A3/sk unknown
- 2001-12-03 EP EP01271992A patent/EP1353927B1/de not_active Expired - Lifetime
- 2001-12-19 AR ARP010105889A patent/AR035524A1/es not_active Application Discontinuation
-
2003
- 2003-07-22 ZA ZA200305659A patent/ZA200305659B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20030062438A (ko) | 2003-07-25 |
| JP4550361B2 (ja) | 2010-09-22 |
| ATE302781T1 (de) | 2005-09-15 |
| PL361733A1 (en) | 2004-10-04 |
| US7019013B2 (en) | 2006-03-28 |
| CN1483035A (zh) | 2004-03-17 |
| WO2002051848A2 (de) | 2002-07-04 |
| ZA200305659B (en) | 2004-08-27 |
| WO2002051848A3 (de) | 2002-10-24 |
| AR035524A1 (es) | 2004-06-02 |
| HUP0302515A3 (en) | 2005-06-28 |
| DE10064994A1 (de) | 2002-07-04 |
| EP1353927A2 (de) | 2003-10-22 |
| CA2432582C (en) | 2011-01-25 |
| US20040063943A1 (en) | 2004-04-01 |
| ES2247007T3 (es) | 2006-03-01 |
| BR0115996A (pt) | 2004-01-06 |
| MXPA03005714A (es) | 2003-10-06 |
| JP2004516329A (ja) | 2004-06-03 |
| EP1353927B1 (de) | 2005-08-24 |
| CA2432582A1 (en) | 2002-07-04 |
| DE50107230D1 (de) | 2005-09-29 |
| SK8432003A3 (en) | 2003-10-07 |
| CZ20031815A3 (cs) | 2003-10-15 |
| HUP0302515A2 (hu) | 2003-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2003122189A (ru) | Сульфамидотиенопиримидины | |
| KR20080105093A (ko) | 1종 이상의 ｐｋｃ 억제제 및 1종 이상의 ｊａｋ3 키나제 억제제를 포함하는, 자가면역성 장애 치료용 제약 조합 조성물 | |
| US4703038A (en) | Combination of dihydropyridines with angiotensin converting enzymes-inhibitors | |
| KR20010083874A (ko) | 약제용 퀴나졸린 유도체 | |
| HRP20000904A2 (en) | Farnesyl protein transferase inhibitors for treating arthropathies | |
| NO20013367L (no) | Colchinolderivater som vaskulorskadende midler | |
| HUP0303315A2 (hu) | Pirazolo [4,3-d] pirimidineket és trombózisellenes szereket, kalcium antagonistákat, prosztaglandinokat vagy prosztaglandinszármazékokat tartalmazó gyógyszerkészítmények | |
| JP2002537258A (ja) | 高血圧の治療のための医薬 | |
| MD523G2 (ro) | Derivaţi noi ai triazolpirimidinei, antagonişti ai receptorilor angiotensinei II, procedee de preparare a lor, compoziţii farmaceutice ce le conţin | |
| JP2002537258A5 (enExample) | ||
| WO2002022111A3 (de) | Kombination von liponsäure und konjuensäuren zur behandlung diabetischer störungen | |
| CA2462799A1 (en) | Pyrimidine derivatives | |
| KR20110093841A (ko) | 자가면역 질환의 치료를 위한 ｄｈｏｄｈ 억제제 및 메토트렉세이트를 포함하는 조합 요법 | |
| US5075308A (en) | Method for treating urinary obstruction | |
| US20040152753A1 (en) | Methods of use for novel sulfur containing organic nitrate compounds | |
| RU2008123811A (ru) | Хиназолины, используемые в качестве модуляторов потенциалзависимых ионных каналов | |
| WO2002049650A3 (de) | Pharmazeutische formulierung enthaltend thienopyrimidine und antithrombotica, calcium-antagonisten, prostaglandine oder prostaglandinderivate | |
| KR101660059B1 (ko) | 중합체 벤질 카르보네이트-유도체 | |
| JP2004250400A (ja) | ピリミジン誘導体 | |
| EP0864568B1 (en) | Agents for treatment of cardiac diseases | |
| JP2010513262A (ja) | カルボニックアンヒドラーゼ阻害剤誘導体 | |
| JPH01503780A (ja) | プロスタサイクリン誘導体含有の局所適用剤 | |
| JP4426654B2 (ja) | 免疫調節用医薬組成物 | |
| AU757114B2 (en) | Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis | |
| JP2004123558A (ja) | 片頭痛の予防、治療剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20050207 |